The case for neuroprotection with dopamine agonists

Clinical Neuropharmacology

Volumn 20, Issue SUPPL. 1, 1997, Pages

  Carvey, Paul M ^a,b   Ling, Zao Dung ^a  

^a Research Center for Brain Repair   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dopamine; Mesencephalon; Parkinson's disease; Pramipexole; Trophic factor

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MESENCEPHALON; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

EID: 0031416375     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199720001-00003     Document Type: Conference Paper

References (50)

1. Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 1992;215:161-70.
2. Camacho-Ochoa M, Walker EL, Evans DL, Piercey MF. Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist. Neurosci Lett 1995;196:97-100.
3. Mierau J, Schneider JF, Ensinger HA, Chio CL, Lajiness ME, Huff RM. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995;290:29-36.
4. Mierau J. Pramipexole: a dopamine-receptor agonist for treatment of Parkinson's disease [Abstract]. Clin Neuropharmacol 1988;96:338.
5. Mireau J, Bechtel WD. SND 919 inhibits dopamine release in vivo and in vitro [Abstract]. Psychopharmacology 1988;96:338.
6. Carter AJ, Muller RE. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991;200:65-72.
7. Robertson GS, Tham CS, Wilson C, Jakubovic A, Fibiger HC. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J Pharmacol Exp Ther 1993;264:1344-51.
8. Piercey MF, Camacho-Ochoa M, Smith MW. Functional roles for dopamine-receptor subtypes. Clin Neuropharmacol 1995;18(suppl 1):S34-42.
9. Hubble JP, Koller WC, Cutler N, et al. Pramipexole, a highly selective dopamine agonist in patients with early Parkinson's disease: an ascending-dose trial. Clin Neuropharmacol 1995;18:338-47.
10. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1987;45:19-34.
11. Calne DB, Zigmond MJ. Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism. Arch Neurol 1991;48:361-3.
12. Adams JD, Odunze IN. Oxygen free radicals and Parkinson's disease. Free Radical Biol Med 1991;10:161-9.
13. Youdim MB, Ben-Shachar D, Riederer P. The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord 1993;8:1-12. [Erratum. Mov Disord 1993;8:225.]
14. Youdim MB, Ben-Shachar D, Riederer P. The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord 1993;8:1-12. [Erratum. Mov Disord 1993;8:225.]
15. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-9.
16. Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992;32(suppl 1):S2-9.
17. Graham DG, Tiffany SM, Bell WR, Gutknecht WF. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978;14:644-53.
18. Fornstedt B, Brun A, Rosengren E, Carlsson A. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm [Park Dis Dement Sect] 1989;1:279-95.
19. Loeffler DA, DeMaggio AJ, Juneau PL, Havaich MK, LeWitt PA. Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation. Clin Neuropharmacol 1994;17:370-9.
20. Ling ZD, Pieri SC, Carvey PM. Comparison of the neurotoxicity of dihydroxyphenylalanine (dopa) stereoisomers in cultured dopamine neurons. Clin Neuropharmacol 1996;19:360-5.
21. Ling ZD, Carvey PM. Pramipexole reduces levodopa-induced dopamine neuron toxicity in tissue culture [Abstract]. Soc Neurosci Abstr 1995;21:242.
22. Carvey PM, Ptak LR, Nath ST, et al. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures. Exp Neurol 1993;120:149-52.
23. Yu SJ, Lo ES, Cochran EJ, et al. Cerebrospinal fluid from patients with Parkinson's disease alters the survival of dopamine neurons in mesencephalic culture. Exp Neurol 1994;126:15-24.
24. Akaneya Y, Takahashi M, Hatanaka H. Survival of a 1-rnethyl-4-phenylpyridinium (MPP*) neurotoxicity against dopaminergic neurons in coculture of rat mesencephalon with their target on non-target regions. Neurosci Res 1995;23:55-63.
25. Prochiantz A, Daguet MC, Di Prozio U, Herbert A, Glowinski J. In vitro studies on central dopaminergic neurons' development. Prog Brain Res 1983;58:365-8.
26. Carvey PM, Ptak LR, Kao L, Klawans HL. Striatal homogenates from animals chronically treated with haloperidol stimulate dopamine and GABA uptake in cultures of rostral mesencephalic tegmentum. Clin Neuropharmacol 1989;12:425-34.
27. Mons N, Tison F, Geffard M. Identification of L-dopa-dopamine and L-dopa cell bodies in the rat mesencephalic dopaminergic cell systems. Synapse 1989;4:99-105.
28. Tison F, Normand E, Jaber M, Aubert I, Bloch B. Aromatic L-amino-acid decarboxylase (DOPA decarboxylase) gene expression in dopaminergic and serotoninergic cells of the rat brainstem. Neurosci Lett 1991;127:203-6.
29. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990;26:428-35.
30. Steece-Collier K, Collier TJ, Sladek CD, Sladek JR. Chronic levodopa impairs morphological development of grafter embryonic dopamine neurons. Exp Neurol 1990;110:201-8.
31. Mena MA, Pardo B, Casarejos MJ, Fahn S, deYebenes JG. Neurotoxicity of levodopa un catecholamine-rich neurons. Mov Disord 1992;7:23-31.
32. Kontur PJ, Marek K, Roth R, Redmond DE. Effects of L-dopa and dopamine receptor agonists on cultured rat mesencephalic dopamine neurons [Abstract]. Neurology 1993;43:A153.
33. Sahakian BJ, Carlson KR, DeGirolami U, Bhawan J. Functional and structural consequences of long-term dietary L-dopa treatment in mice. Commun Psychopharmacol 1980;4:169-76.
34. Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-5.
35. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 1984;43:990-3.
36. 3]mazindol autoradiography. Neuroscience 1991;43:95-110.
37. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-33.
38. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-12.
39. Olanow CW. A radical hypothesis for neurodegeneration [see Comments]. Trends Neurosci 1993;16:439-44.
40. Von Voigtlander PF, Althaus JS, Hall ED, Huff RM, Sethy VH, Carvey PM. Neuroprotection by pramipexole, a D3 preferring dopamine agonist [Abstract]. Proc Am Coll Neuropathol 1995;37.
41. Dal Toso R, Giorgi O, Soranzo C, et al. Development and survival of neurons in dissociated fetal mesencephalic serum-free cell cultures. I. Effects of cell density and of an adult mammalian striatal-derived neuronotrophic factor (SDNF). J Neurosci 1988;8:733-45.
42. Mayer E, Dunnett SB, Pellitteri R, Fawcett JW. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons-I. Effects in vitro. Neuroscience 1993;56:379-88.
43. Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 1991;564:203-19.
44. Tomozawa Y, Appel SH. Soluble striatal extracts enhance development of mesencephalic dopaminergic neurons in vitro. Brain Res 1986;399:111-24.
45. Emerit MB, Segovia J, Alho H, Mastrangelo MJ, Wise BC. Hippocampal membranes contain a neurotrophic activity that stimulates cholinergic properties of fetal rat septal neurons cultured under serum-free conditions. J Neurochem 1989;52:952-61.
46. Lambert MP, Megerian T, Garden G, Klein WL. Soluble proteins from rat olfactory bulb promote the survival and differentiation of cultured basal forebrain neurons. Brain Res 1988;469:263-76.
47. Carvey PM, Ptak LR, Lin D, et al. Alterations in striatal neurotrophic activity induced by dopaminergic drugs. Pharmacol Biochem Behav 1993;46:195-204.
48. Carvey PM, Ptak LR, Lo ES, et al. Levodopa reduces the growth promoting effects of striatal extracts on rostral mesencephalic tegmentum cultures. Exp Neurol 1991;11:28-34.
49. Lo ES, Lin DH, Carvey PM. Temporal pattern of haloperidol-induced growth promoting activity: effect of treatment duration and withdrawal [Abstract]. Soc Neurosci Abstr 1993;18:630.
50. Jiang DH, Reches A, Wagner HR, Fahn S. Biochemical and behavior evaluation of pergolide as a dopamine agonist in the rat brain. Neuropharmacology 1984;23:295-301.